Unbranded Infliximab Infusion Therapy in New York

No. Unbranded infliximab is not a biosimilar, and it is not a generic. It is Janssen Biotech's own infliximab — the same product marketed as Remicade, sold without the brand name on the carton. Its DailyMed label is listed under Janssen Biotech, Inc. and carries no biosimilarity statement, which is the sentence FDA requires on the label of a product licensed as a biosimilar. If you have been told you are getting "the generic version of Remicade," that description does not match the labeling.

The confusion is understandable, and it has consequences. With ordinary small-molecule drugs, an unbranded name usually signals a generic copy made by a different manufacturer. Biologics do not work that way. A biosimilar is a separate product with its own Biologics License Application, licensed under section 351(k) of the Public Health Service Act on data showing it is highly similar to a reference product. Remicade is that reference product, licensed under section 351(a), with an initial U.S. approval of 1998. Unbranded infliximab did not come through the 351(k) pathway, because it is not a copy of Remicade.

Three things go wrong when the label is misread. A prescriber may order it believing a biosimilar has been ordered. A prior authorization may be built against the wrong product's criteria. And a patient may believe they have been switched to a different medicine when, on the labeling, they have not. Cigna's own coverage policy adds to the impression by listing it as "infliximab (authorized generic)".

One caution about the name itself. The phrase "unbranded infliximab" is also used loosely to describe unbranded presentations of a biosimilar. This page describes infliximab as FDA labels it and makes no claim about which specific product or NDC is supplied for any particular order. Confirm the exact product with the prescribing physician and with our care team before treatment starts — and if the answer matters to a prior authorization, get it in writing.

The difference is the licensing pathway, and it is visible in the nonproprietary name: a biosimilar carries a four-letter suffix, and unbranded infliximab does not.

FDA describes a biosimilar to patients as a biologic that "is highly similar to a biologic medication already approved by FDA — the original biologic (also called the reference product)", and the biosimilar labels themselves state that approval rests on data showing "there are no clinically meaningful differences between [the biosimilar product] and the reference product." That is a statement about similarity, not about ranking, and Prime Infusions does not recommend one infliximab product over another.

No infliximab product carries FDA interchangeability — not the originator, not the unbranded version, not any biosimilar. Each biosimilar above is listed in the FDA Purple Book as "351(k) Biosimilar," and none appears with an interchangeability designation on FDA's biosimilar product list. As FDA explains, an interchangeable product "is a biosimilar that may be substituted without consulting the prescribing doctor," subject to state law — a dispensing designation, not a claim that a product performs better.

Can a pharmacy substitute one infliximab product for another?

Because no infliximab product is designated interchangeable, the automatic-substitution route does not exist here. New York's substitution statute, Education Law § 6816-a, requires a pharmacist to substitute a biological product only where "the substituted biological product is either an interchangeable biological product for the prescribed product or the substituted biological product is one for which the prescribed product is an interchangeable biological product," and only where "the prescriber does not designate that a substitution is prohibited." With no interchangeable infliximab in existence, that pathway is unavailable for infliximab in New York.

The second reason is the route of administration. Infliximab is provider-administered under the medical benefit, not dispensed at a retail counter: CMS covers it under Part B as a drug given "as part of (or incident to) a physicians' service" rather than one that is usually self-administered. The product a patient receives is the product the prescriber orders and the infusion site acquires. There is no pharmacy substitution step anywhere in that workflow.

So what actually determines the product? The prescriber's order, interacting with the health plan's product policy. Payers commonly designate certain infliximab products as preferred and require a documented trial of one of them before covering a non-preferred product — enforced through prior authorization, not at a pharmacy counter. That is a coverage decision made by the plan, not a clinical ranking, and it is covered further down this page.

The eight indications below are section 1 of the FDA-approved prescribing information for infliximab (Janssen Biotech), revised 3/2025 — the unbranded product's own label, read directly rather than inferred from its brand-name counterpart. Unbranded infliximab is licensed under the same BLA as REMICADE (infliximab) — BLA 103772, initial U.S. approval 1998 — carries no four-letter suffix and no biosimilarity statement, and its labeled indications are identical to Remicade's. Approved indications still differ by product across the infliximab class, so the label for the specific product ordered is always the one that governs.

Two points are commonly misstated. Rheumatoid arthritis is a combination indication — the labeled indication is in combination with methotrexate, and listing rheumatoid arthritis without that qualifier misstates it. And the pediatric indications stop at Crohn's disease and ulcerative colitis in patients 6 and older: there is no pediatric indication for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis, all of which are adult-only.

Off-label use, stated plainly. Any use outside the eight indications above — hidradenitis suppurativa, uveitis, sarcoidosis, Behcet's disease, pyoderma gangrenosum, graft-versus-host disease — and any pediatric use other than Crohn's disease and ulcerative colitis at age 6 and older, is not FDA-approved for that use. Medicare contractor billing guidance does contemplate infliximab claims for pyoderma gangrenosum with coexisting inflammatory bowel disease under specific paired ICD-10 coding rules, but that is a coverage pathway, not an FDA indication.

A formulation note. Everything on this page concerns intravenous infliximab. Subcutaneous infliximab (Zymfentra) is a different product with its own labeling, dispensed under the pharmacy benefit rather than administered in an infusion suite. The two should not be blended together when discussing a switch.

Every indication uses the same induction schedule — infusions at weeks 0, 2 and 6 — followed by a maintenance interval. Dosing is weight-based in mg/kg, which is why weight is measured at each visit; Medicare's billing article for infliximab and biosimilars expects patient weight in the record.

Two details are easy to get wrong on a scheduling call. Rheumatoid arthritis is the only indication that starts at 3 mg/kg rather than 5, and ankylosing spondylitis is the only one maintained every 6 weeks rather than every 8.

Each infusion runs a labeled minimum of two hours. The prescribing information states that "the infusion must be administered intravenously for at least 2 hours with an infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding filter (pore size of 1.2 µm or less)." That floor is the FDA-approved administration instruction, not a clinic convention, and the US label contains no shortened or one-hour infusion option. Your total visit is longer than the infusion itself, because it also includes check-in and weighing, vascular access and pre-infusion assessment, any premedication the prescriber has ordered, and preparation of the drug.

On premedication, the label is permissive rather than prescriptive: patients "may be premedicated with histamine-1 receptor antagonists, histamine-2 receptor antagonists, acetaminophen, and/or corticosteroids." Whether you receive any is the prescriber's decision. The label also directs that before treatment, appropriate personnel and medication are available to treat reactions that occur during and shortly after the infusion, that the infusion may be slowed or stopped for mild to moderate reactions, and that the infusion is discontinued if a serious reaction occurs.

Infliximab labeling carries an FDA boxed warning headed WARNING: SERIOUS INFECTIONS and MALIGNANCY. It is reproduced below as printed in the REMICADE prescribing information (rev. 2/2025). The same boxed warning, with the product name substituted, appears on the Inflectra, Renflexis and Avsola labels — no infliximab product carries a lesser warning.

SERIOUS INFECTIONS

Patients treated with REMICADE are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

REMICADE should be discontinued if a patient develops a serious infection or sepsis.

Reported infections include:

• Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before REMICADE use and during therapy. Treatment for latent infection should be initiated prior to REMICADE use.
• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
• Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with REMICADE should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with REMICADE, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including REMICADE.

Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including REMICADE. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of reported REMICADE cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males.

What the label reports on side effects

In the rheumatoid arthritis trials summarized in the label, adverse reactions in at least 5% of patients receiving four or more infusions (n=1129, versus placebo n=350) included upper respiratory tract infection 32% (placebo 25%), nausea 21% (20%), headache 18% (14%), sinusitis 14% (8%), diarrhea 12% (12%), abdominal pain 12% (8%), pharyngitis 12% (8%), coughing 12% (8%), bronchitis 10% (9%), rash 10% (5%), dyspepsia 10% (7%), fatigue 9% (7%), urinary tract infection 8% (6%), arthralgia 8% (7%), pruritus 7% (2%), fever 7% (4%) and hypertension 7% (5%). As the label itself frames it, clinical trial rates are observed under widely varying conditions and cannot be directly compared with rates in other trials or with rates seen in practice. Pediatric rates were not extracted here and should not be assumed equal to adult rates.

Infusion reactions. The label reports that "approximately 20% of REMICADE-treated patients experienced an infusion reaction compared with 10% of placebo-treated patients," occurring during an infusion or within 1 hour after one. Across all infusions, 3% were accompanied by nonspecific symptoms such as fever or chills, 1% by cardiopulmonary reactions (primarily chest pain, hypotension, hypertension or dyspnea), and under 1% by pruritus or urticaria. "Serious infusion reactions occurred in <1% of patients and included anaphylaxis, convulsions, erythematous rash and hypotension." That is why the infusion is supervised throughout and why trained staff and emergency medication are required to be on hand.

Prime Infusions has 13 infusion centers in New York, plus one in Atlanta. In New York that means Brooklyn (Foster Avenue) and Boro Park in Brooklyn; Fresh Meadows, Astoria, Jamaica and Howard Beach in Queens; the Upper East Side in Manhattan; Staten Island; Great Neck in Nassau County and Inwood in the Five Towns; Port Jefferson Station in Suffolk County; and New City in Rockland County and Monroe in Orange County. All centers are open Monday to Friday, 9:00AM to 5:00PM, and addresses are on our locations page.

Because maintenance runs on a fixed 6- or 8-week interval for years at a time, the practical question is usually which center is reachable on a weekday. Our care team confirms which location will administer your infusions, and which infliximab product the order specifies — per-center product availability is not published on this site, and with unbranded infliximab in particular it is worth asking before the first appointment is booked.

Which type of site is covered is a separate question, decided by the plan. UnitedHealthcare's commercial policy "Provider Administered Drugs – Site of Care," Policy 2026D0121V, effective August 1, 2026, lists Remicade, Inflectra, Renflexis and Avsola within scope and states that "alternative sites of care, such as non-hospital outpatient infusion, physician office, ambulatory infusion suites, or home infusion services are well accepted places of service for medication infusion therapy," and that where an individual does not meet criteria for outpatient hospital facility infusion, alternative sites of care may be used. Whether that policy applies to any particular patient is a determination only that patient's plan can make.

Physicians can send a referral through our Treatment Referrals directory. Patients and families can reach us at 718-443-4000 or through our contact page.

Expect prior authorization, and expect a question about which infliximab product. Most patients assume the originator or its unbranded version is the default. On the two national policies below, it is not.

UnitedHealthcare, Commercial Medical Benefit Drug Policy "Infliximab (Avsola, Inflectra, Remicade, & Renflexis)," Policy 2026D0004AR, effective February 1, 2026, names Inflectra and Avsola as its preferred products. To obtain Remicade, Renflexis or another non-preferred infliximab under medical-necessity plans, the policy asks for "documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response to therapy and residual disease activity," plus prescriber attestation, or "documentation of intolerance, contraindication, or adverse event to Inflectra or Avsola."

Cigna, "Infliximab Intravenous Products Preferred Specialty Management Policy," Coverage Policy PSM005, effective 08/15/2026, lists Avsola and Inflectra as preferred and names "infliximab (authorized generic), Remicade, Renflexis" as non-preferred — so on that policy, unbranded infliximab sits on the non-preferred side, and the policy directs the patient to try at least one preferred product before a non-preferred one is approved. Its narrow exception is a patient who tried Inflectra or Avsola and cannot continue "due to a formulation difference in the inactive ingredient(s)" that, according to the prescriber, would cause a significant allergy or serious adverse reaction. This is payer policy, not a clinical ranking; product lists change, and both policies above are national rather than New York-specific.

Medicare. Infliximab falls under Part B, not Part D, because it is administered by a clinician: CMS states Part B covers drugs "provided as part of (or incident to) a physicians' service" and generally "only drugs that are not usually self-administered." Medicare pays ASP plus 6% for most separately payable Part B drugs; for biosimilars the limit is the biosimilar's ASP plus 6% of the reference biological's ASP, or plus 8% for qualifying biosimilars. The contractor billing article for infliximab and biosimilars (A52423) requires documentation including patient weight, tuberculosis evaluation and treatment initiated before therapy, and inadequate response to a three-month trial of conventional non-biologic therapy — so TB screening is both a safety step and a claims requirement. What a beneficiary personally owes depends on the deductible, coinsurance and any supplemental coverage, and cannot be stated in the abstract.

Prime Infusions verifies benefits and submits the authorization request together with your prescriber. Coverage, prior authorization and out-of-pocket cost are determined solely by your health plan, and no infusion provider can guarantee an approval.